Incidence and management of gynecomastia in men treated for prostate cancer

Journal of Urology

Volumn 174, Issue 5, 2005, Pages 1737-1742

  Dobs, Adrian ^a   Darkes, Malcolm J M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Rainbow Beach Pharmacy   (Australia)

Author keywords

Breast diseases; Complications; Gynecomastia; Prostate; Prostatic neoplasms

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIANDROGEN; AROMATASE INHIBITOR; BICALUTAMIDE; DIETHYLSTILBESTROL; ESTROGEN; TAMOXIFEN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FOLLOW UP; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; ORCHIECTOMY; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SURGICAL TECHNIQUE;

EID: 27544498812     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000176461.75794.f8     Document Type: Review

References (35)

1. Rohrich, R. J., Ha, R. Y., Kenkel, J. M. and Adams, W. P., Jr.: Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. Plast Reconstr Surg, 111: 909, 2003
2. Fruhstorfer, B. H. and Malata, C. M.: A systematic approach to the surgical treatment of gynaecomastia. Br J Plast Surg, 56: 237, 2003
3. van Andel, G. and Kurth, K. H.: The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol, 44: 209, 2003
4. Green, H. J., Pakenham, K. I., Headley, B. C. and Gardiner, R. A.: Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology, 11: 401, 2002
5. Ockrim, J. L., Lalani, E.-N., Laniado, M. E., Carter, S. S. C. and Abel, P. D.: Transdermal estradiol therapy for advanced prostate cancer-forward to the past? J Urol, 169: 1735, 2003
6. Wortsman, J., Hamidinia, A. and Winters, S. J.: Hypogonadism following long-term treatment with diethylstilbestrol. Am J Med Sci, 297: 365, 1989
7. Physicians' Desk Reference. Montvale: Medical Economics, 2003
8. Castro-Magana, M., Angulo, M. and Uy, J.: Male hypogonadism with gynecomastia caused by late-onset deficiency of testicular 17-ketosteroid reductase. N Engl J Med, 328: 1297, 1993
9. Smyth, C. M. and Bremner, W. J.: Klinefelter syndrome. Arch Intern Med, 158: 1309, 1998
10. See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D. et al: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol, 168: 429, 2002
11. Wirth, M., Tyrrell, C., Wallace, M., Delaere, K. P., Sanchez-Chapado, M., Ramon, J. et al: Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology, 58: 146, 2001
12. Bales, G. T. and Chodak, G. W.: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology, suppl., 47: 38, 1996
13. Chodak, G., Sharifi, R., Kasimis, B., Block, N. L., Macramalla, E. and Kennealey, G. T.: Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology, 46: 849, 1995
14. Denis, L. J., Keuppens, F., Smith, P. H., Whelan, P., de Moura, J. L., Newling, D. et al: Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol, 33: 144, 1998
15. Hedlund, P. O. and Henriksson, P.: Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology, 55: 328, 2000
16. Iversen, P., Tyrrell, C. J., Kaisary, A. V., Anderson, J. B., van Poppel, H., Tammela, T. L. et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 164: 1579, 2000
17. Kotake, T., Usami, M., Akaza, H., Koiso, K., Homma, Y., Kawabe, K. et al: Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group. Jpn J Clin Oncol, 29: 562, 1999
18. Potosky, A. L., Knopf, K., Clegg, L. X., Albertsen, P. C., Stanford, J. L., Hamilton, A. S. et al: Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol, 19: 3750, 2001
19. Schellhammer, P. F., Sharifi, R., Block, N. L., Soloway, M. S., Venner, P. M., Patterson, A. L. et al: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology, 50: 330, 1997
20. Shakir, S., Pearce, G. and Mann, R. D.: Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription-event monitoring data. BJU Int, 87: 789, 2001
21. Marshall, W. A. and Tanner, J. M.: Variations in pattern of pubertal changes in girls. Arch Dis Child, 44: 291, 1969
22. Iwuagwu, O. C., Calvey, T. A., Ilsley, D. and Drew, P. J.: Ultrasound guided minimally invasive breast surgery (UMIBS): a superior technique for gynecomastia. Ann Plast Surg, 52: 131, 2004
23. Boljanovic, S., Axelsson, C. K. and Elberg, J. J.: Surgical treatment of gynecomastia: liposuction combined with subcutaneous mastectomy. Scand J Surg, 92: 160, 2003
24. Colombo-Benkmann, M., Buse, B., Stern, J. and Herfarth, C.: Indications for and results of surgical therapy for male gynecomastia. Am J Surg, 178: 60, 1999
25. Widmark, A., Fossa, S. D., Lundmo, P., Damber, J. E., Vaage, S., Damber, L. et al: Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology, 61: 145, 2003
26. Waterfall, N. B. and Glaser, M. G.: A study of the effects of radiation on prevention of gynaecomastia due to oestrogen therapy. Clin Oncol, 5: 257, 1979
27. Tyrrell, C., Morris, T. and Carroll, K.: Prophylactic breast irradiation significantly reduces the incidence of bicalutamide-induced gynaecomastia. Eur Urol, 1: 136, 2002
28. McDermott, M. T., Hofeldt, F. D. and Kidd, G. S.: Tamoxifen therapy for painful idiopathic gynecomastia. South Med J, 83: 1283, 1990
29. Parker, L. N., Gray, D. R., Lai, M. K. and Levin, E. R.: Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism, 35: 705, 1986
30. Serels, S. and Melman, A.: Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation. J Urol, 159: 1309, 1998
31. Staiman, V. R. and Lowe, F. C.: Tamoxifen for flutamide/finasteride- induced gynecomastia. Urology, 50: 929, 1997
32. Ting, A. C., Chow, L. W. and Leung, Y. F.: Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg, 66: 38, 2000
33. Boccardo, F., Rubagotti, A., Garofalo, L., Di Tonno, P., Conti, G., Bertaccini, A. et al: Tamoxifen (T) is more effective than Anastrozole (A) in preventing gynecomastia induced by Bicalutamide (B) monotherapy in prostate cancer (pea) patients (pts). Presented at annual meeting of American Society of Clinical Oncology, Chicago, Illinois, May 31-June 3, 2003
34. Braunstein, G. D.: Aromatase and gynecomastia. Endocr Relat Cancer, 6: 315, 1999
35. Plourde, P. V., Reiter, E. O., Jou, H. C., Desrochers, P. E., Rubin, S. D., Bercu, B. B. et al: Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab, 89: 4428, 2004